- Rapid growth & expansion
- Xeno-free, contains no components of animal origin
- Fully supplemented, one bottle ready-to-go
High-efficiency xeno-free isolation and expansion of both adipose and bone marrow-derived MSCs, without plate coating.
|Content||500 ml, Frozen medium|
The CnT-Prime MSC-XF medium enables high-efficiency isolation and expansion of both adipose and bone marrow-derived MSCs, without plate coating, in a fully xeno-free environment that can be upgraded for clinical use.
The new CnT-Prime MSC-XF medium enables high efficiency isolation and expansion of both adipose and bone marrow derived MSCs, without plate coating, in a fully xeno-free environment that can be upgraded for clinical use!
Figure: BM-MSC (P4) and AD-MSC (P6) growing in CnT-PR-MSC-XF medium.
Cells growing in CnT-Prime MSC-XF medium also demonstrate extended longevity and remain strongly multipotent for at least 4 passages.
Cells can be induced to differentiate down adipogenic, osetogenic or chondrogenic lineages following addition of the corresponding differentiation supplement.
Figure: Adipogenesis in BM-MSC (P4). Cells growing in CnT-PR-MSC-XF medium remain strongly multipotent for extended periods. Images courtesy of Institute of Surgical Technology and Biomechanics, University of Bern.
For an overview of the performance of bone marrow-derived MSC in CnT-PR-XF medium, please download this A4 Flyer.
Adipose-derived MSC expanded in CnT-PR-MSC-XF are CD45-/CD31-/CD73+/CD90+/CD105+/CD34+/-, and importantly at least 8% of the cell population remains CD34-positive at passage 4.
Figure: CD34 expression in AD-MSC, CnT-PR-MSC-XF medium, passage 4. Analysis courtesy of Dr Sean Hall, Dept Clinical Research, University of Bern.
AD-MSC expanded in CnT-Prime MSC-XF medium also maintain strong multipotency for extended periods, with class leading differentiation efficiency after 4 passages in culture.
Figure: CnT-Prime MSC Media demonstrate high adipogenic differentiation efficiency compared with leading competitors after 4 passages in culture. (A) CnT-PR-MSC-CD, (B) CnT-PR-MSC-XF, (C) Mesencult-ACF
|Sourcing of human peripheral blood-derived myeloid angiogenic cells under xeno-free conditions for the treatment of critical limb ischemia||Christy Wing Tung Wong, Apurva Sawhney, Yalan Wu, Yi Wah Mak, Xiao Yu Tian, Hon Fai Chan, Anna Blocki||2022||Other|